Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects
NCT01454973 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25
Last updated 2012-08-10
Summary
A multi-year clinical study to improve tools for measuring the function of insulin-producing beta cells in people with type 2 diabetes mellitus.
Conditions
Sponsors & Collaborators
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
collaborator NIH -
Juvenile Diabetes Research Foundation
collaborator OTHER -
Amylin Pharmaceuticals, LLC.
collaborator INDUSTRY - collaborator INDUSTRY
- collaborator INDUSTRY
- collaborator INDUSTRY
- collaborator INDUSTRY
-
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
collaborator INDUSTRY - collaborator INDUSTRY
-
Foundation for the National Institutes of Health
lead OTHER
Principal Investigators
-
George Atiee, M.D. · ICON Development Solutions
Eligibility
- Min Age
- 30 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-10-31
- Primary Completion
- 2012-01-31
- Completion
- 2012-01-31
Countries
- United States
Study Locations
More Related Trials
-
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
NCT01686945 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
NCT07313813 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Insulin Secretion in Diabetes Before and After Glycemic Control
NCT00469833 ·Status: COMPLETED ·Phase: NA
-
Study of Weight Loss Using Gastric Stimulation in Obese Patients With Type 2 Diabetes
NCT00200018 ·Status: COMPLETED ·Phase: NA
-
Surgical Treatment of Type 2 Diabetes in Non-Morbidly Obese Patients
NCT00596973 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
NCT05093517 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin
NCT04034524 ·Status: UNKNOWN
-
Exercise and GLP-1 RA on Insulin Secretion
NCT04383197 ·Status: UNKNOWN ·Phase: NA
-
Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes
NCT06825182 ·Status: RECRUITING ·Phase: PHASE3
-
Alpha-Cell Sensitivity to GLP-1 in Patients With Type 2 Diabetes
NCT00497133 ·Status: COMPLETED
-
The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)
NCT01449019 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes
NCT01509742 ·Status: COMPLETED ·Phase: PHASE1
-
Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose
NCT01919788 ·Status: COMPLETED ·Phase: NA
-
Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
NCT05597202 ·Status: UNKNOWN ·Phase: PHASE4
-
Circulating Biomarkers in the Development of Type 1 Diabetes
NCT05505669 ·Status: RECRUITING
-
A Study of Dulaglutide in Chinese Participants
NCT01667900 ·Status: COMPLETED ·Phase: PHASE1
-
Liraglutide in Newly Onset Type 1 Diabetes.
NCT01879917 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus
NCT00445627 ·Status: COMPLETED
-
The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans
NCT01953393 ·Status: COMPLETED ·Phase: NA
-
The Role of Amylin and Incretins on Postprandial Metabolisms in Adolescents With Type 2 Diabetes Mellitus (T2DM).
NCT00361946 ·Status: COMPLETED
-
Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?
NCT03954873 ·Status: COMPLETED ·Phase: NA
-
A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
NCT04143945 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp
NCT05456854 ·Status: WITHDRAWN ·Phase: PHASE1
-
Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function
NCT01790308 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
NCT02584582 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3